Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540374 | PMC |
http://dx.doi.org/10.3350/cmh.2024.0394 | DOI Listing |
This editorial explores the intricate landscape of supplement use in oncology, highlighting the growing interest and challenges surrounding their integration into cancer care. It discusses the disparity in regulatory oversight between supplements and pharmaceutical drugs, the blurred lines in their classification, and the ethical complexities in patient-doctor communication. The importance of transparency, shared decision-making, and realistic expectations is emphasized.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
January 2025
Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, IMIBIC, Córdoba, Spain.
Paediatr Drugs
January 2025
Department of Development and Regeneration, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Nat Chem
January 2025
Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan.
Infect Chemother
December 2024
Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!